Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte ...

Investor interest in artificial intelligence-powered drug discovery shows little signs of wearing off, as start-up Genesis Therapeutics rakes in an impressive $200 million in an oversubscribed ...

(RTTNews) - Thursday, Incyte Corp. (INCY) and Genesis Therapeutics have entered into a strategic partnership focused on the research, discovery, and development of small molecule medicines.

Incyte and Genesis Therapeutics have entered a strategic partnership aimed at the research, discovery and development of new small-molecule medicines. Incyte will choose the initial collaboration ...

On February 20, Incyte and Genesis Therapeutics formed a collaboration to develop novel small-molecule medicines using AI ...

Incyte Corporation (NASDAQ:INCY) develops and markets biopharmaceutical treatments for cancer, immune disorders, and other diseases across global markets. On February 20, Incyte and Genesis ...

WILMINGTON, Del. & BURLINGAME, Calif., February 20, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic ...